FDA grants Prescient Therapeutics (ASX:PTX) broad orphan drug status for PTX-100 cancer treatment
Oncology company Prescient Therapeutics (PTX) has been granted broad orphan drug designation (ODD) for its...
Oncology company Prescient Therapeutics (PTX) has been granted broad orphan drug designation (ODD) for its...
Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to...
Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M.
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.